Nivolumab
Chordoma
Sarcoma Oncology Research Center, LLCmonoclonal_antibodyPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Chordoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ipilimumab National Cancer Institute (NCI) | Phase 2 | CCC |
Nab-Rapamycin Sarcoma Oncology Research Center, LLC | Phase 1/2 | CCC |
Zoledronate University of Florida | Phase 1/2 | CCC |
FLUDEOXYGLUCOSE National Cancer Institute (NCI) | Phase 1/2 | CCC |
Tiragolumab National Cancer Institute (NCI) | Phase 1/2 | CCC |
View all 13 →
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →